GlassScriptPhysician profile
Michael James Coleman
NPI 1598085979
$19,714.41
in general payments reported to CMS, 2019-2025
16 companies · $9,725 in 2025
The $9,725 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,871 · 2020: $11.29 · 2021: $1,268 · 2022: $133 · 2023: $167 · 2024: $538 · 2025: $9,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Travel and Lodging: $2,899 · Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Travel and Lodging | $2,899.04 |
| Food and Beverage | $1,531.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $9,538.18 | 2023-2025 | Stellaris, Akreos Ao Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,521.25 | 2019-2020 | |
| Eyepoint US, INC. | $1,000.00 | 2021 | |
| Alcon Vision LLC | $320.08 | 2019-2024 | Hydrus Microstent |
| Biotissue Holdings INC. | $279.08 | 2022-2024 | |
| Allergan, INC. | $210.58 | 2021 | |
| Kala Pharmaceuticals, INC. | $169.53 | 2019 | |
| Glaukos Corporation | $155.81 | 2023-2025 | Photrexa, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $103.06 | 2024-2025 | |
| Sight Sciences, INC. | $77.49 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $71.65 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $58.89 | 2021-2022 | |
| Dompe US, INC. | $52.30 | 2025 | Oxervate |
| Abbvie INC. | $46.41 | 2024-2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $45.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.